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The accepted paradigms and treatment strategies for heart
failure have changed during the past 50 years. Traditionally,
patients with CHF were treated with diuretics, vasodilators
and inotropic drugs, resulting in improvement in functional
status and symptoms, but with no decrease in long-term
mortality [1,2]. However, the initial haemodynamic dysfunc-
tion of CHF has downstream effects on cardiovascular
reflexes, and systemic organ perfusion and function. The
arterial under-filling is sensed by baroreceptors that activate
powerful neurohormones, which act as effectors of vasocon-
striction and of avid sodium and water retention. Recognition
of neurohormones as important substances in the pathogen-
esis of CHF has resulted in several new treatment modali-
ties, including angiotensin-converting enzyme (ACE)
inhibitors, aldosterone antagonists and β-blockers, which
yield marked improvements in morbidity and mortality of CHF
patients [3–7].
Despite ‘state of the art’ cardiovascular treatment, CHF is still
a progressive disease with high morbidity and mortality, sug-
gesting that important pathogenic mechanisms remain active
and unmodified by the present treatment modalities. Persis-
tent immune activation and inflammation may represent such
‘unmodified mechanisms’. Attention has focused on media-
tors that are classically associated with innate immunity,
including inflammatory cytokines [8].
Cytokines as pathogenic mediators of chronic
heart failure
Cytokines are peptides that mediate cell-to-cell interactions
via specific cell-surface receptors. They regulate activation,
differentiation, growth, death and acquisition of effector func-
tions of various cell types [9]. As a result, they are increas-
ingly recognized as important factors in the pathophysiology
of CHF (Fig. 1).
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Abstract
Inflammatory cytokines may negatively influence contractility and contribute to the remodelling process
in the failing myocardium. Traditional cardiovascular drugs appear to have little influence on the overall
cytokine network in chronic heart failure (CHF). Increased interest in anticytokine therapy has therefore
evolved. Several small studies have used tumour necrosis factor (TNF)-α as a target, resulting in
improved functional capacity and myocardial performance. Intravenous immunoglobulin (IVIG)
represents another therapeutic approach in which the impact on myocardial performance appears to
be correlated with anti-inflammatory effects. These studies demonstrate potential for immuno-
modulation as a therapy in addition to conventional cardiovascular treatment in CHF, but the most
effective drugs in this regard have yet to be identified.
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Several studies have demonstrated that CHF patients are
characterized by persistent immune activation in vivo. This is
reflected in increased circulating levels of inflammatory
cytokines (TNF-α, IL-1β and IL-6) and chemokines (monocyte
chemoattractant protein [MCP]-1 and IL-8), as well as
enhanced expression of various inflammatory mediators
(TNF-α, IL-6 and adhesion molecules) within the failing
myocardium, independent of the cause of CHF [10–20].
Although there is a lack of specificity of cytokine activation in
patients with CHF, several lines of evidence suggest that
these inflammatory mediators are not only markers of immune
activation (an epiphenomenon in severely ill patients), but may
also play a pathogenic role in CHF. The pathogenic role of
inflammatory cytokines in CHF is supported by research con-
ducted in mouse models. First, transgenic mice with cardiac-
specific over-expression of TNF-α developed dilated
cardiomyopathy [21]. Second, systemic administration of
TNF-α, even at concentrations comparable to those found in
the circulation of CHF patients, have been shown to induce a
dilated-cardiomyopathy-like phenotype in animal models [22].
Inflammatory cytokines may modulate cardiovascular func-
tions by a variety of mechanisms (Fig. 1). Cytokines such as
TNF-α and IL-1β have been shown to depress myocardial
contractility. This may be due to uncoupling of β-adrenergic
signalling, increase in cardiac nitric oxide, or alterations in
intracellular calcium homeostasis [23–26]. TNF-α, and
members of the IL-6 family, may also induce structural
changes in the failing myocardium such as cardiomyocyte
hypertrophy and interstitial fibrosis [27,28]. Additionally,
TNF-α and IL-1β may promote cardiomyocyte apoptosis as
well as activate metalloproteinases and impair the expression
of their inhibitors, possibly contributing to cardiac remodelling
[29–31].
Stimuli for cytokine expression in chronic
heart failure
Autoimmunity and various microbes are known to play patho-
genic roles in subgroups of idiopathic dilated cardiomyopathy
(IDCM) patients, and such mechanisms could clearly
promote enhanced cytokine levels in CHF. However, raised
cytokine levels appear not to be restricted to IDCM, but are
also found in ischaemic cardiomyopathy. Infection with
certain microbes (Chlamydia pneumoniae. and
cytomegalovirus) has recently been suggested to be involved
in the pathogenesis of atherosclerosis. Microbial antigens
may also induce myocardial damage through molecular
mimicry (Fig. 1) [32–34]. Moreover, endotoxins have been
suggested to trigger immune activation in patients with CHF
during oedematous episodes, possibly following leakage from
the gastrointestinal tract [35]. Accordingly, persistent stimula-
tion by microbial antigens might well lead to cytokine activa-
tion in CHF patients (Fig. 1). Elevation in cytokine levels
seems to occur in CHF independently of chronic infection,
however, and several other factors may lead to an enhanced
inflammatory response in such patients.
Both mechanical overload and shear stress may induce
cytokine expression (MCP-1 and IL-8) in both endothelial and
smooth muscle cells [36]. Moreover, hypoxia and ischaemia
have been found to be potent inducers of inflammatory
cytokines (TNF-α, MCP-1 and IL-8) within the myocardium.
This may occur through production of reactive oxygen
species, with secondary activation of the transcriptional
factor nuclear factor-κB [37,38]. Finally, oxidized low-density
lipoprotein cholesterol may increase cytokine expression
Figure 1
Overview of potential inflammatory mechanisms that are involved in the
development of chronic heart failure (CHF). Various stimuli, including
autoimmunity, chronic infections, mechanical overload, ischaemia and
oxidized low-density lipoprotein (LDL)-cholesterol, may induce
production of inflammatory cytokines in CHF. Inflammatory cytokines
may further negatively influence contractility and contribute to the
remodelling process in the failing myocardium (e.g. hypertrophy and
apoptosis of cardiomyocytes), resulting in a cardiomyopathy-like
phenotype with cardiac dilatation and fibrosis. IL=interleukin;
MCP=monocyte chemoattractant protein; TNF=tumour necrosis factor.
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(IL-1β, TNF-α, IL-6 and IL-8) in endothelial cells and mono-
cytes, and such mechanisms may be of particular importance
in myocardial failure secondary to coronary artery disease
[39]. The relative importance of the stimuli for cytokine pro-
duction in various forms of CHF is uncertain, however.
Are parameters of immune activation
prognostic markers in chronic heart failure?
The persistent immune activation in CHF has been reported
to occur independently of the aetiology of heart failure
[11,18], possibly representing a final common pathogenic
pathway in this disorder. Several studies have reported raised
plasma levels of inflammatory cytokines in direct relation to
deterioration of functional class and cardiac performance (left
ventricular ejection fraction [LVEF]) [11–13]. Even more
importantly, it appears that these inflammatory mediators may
provide important prognostic information in CHF patients. For
example, in a substudy of the Studies on Left Ventricular Dys-
function (SOLVD) [13], patients with TNF-α plasma levels of
less than 6.5 pg/ml had a better prognosis than did patients
with higher levels. Moreover, in a recent report from a large
population of CHF patients (the cytokine database from the
Vesnarinone Trial [VEST]) [40,41], circulating levels of inflam-
matory cytokines (TNF-α and IL-6) and cytokine receptors
(soluble TNF receptors) were found to be independent pre-
dictors of mortality in patients with advanced heart failure.
These new clinical data further support the notion that raised
levels of cytokines in CHF patients are not only epiphenom-
ena, but also may reflect important pathogenic mechanisms
in such patients.
Effect of cardiovascular therapy on cytokine
levels in chronic heart failure patients
There are few data on how traditional cardiovascular medica-
tions influence the persistent immune activation that occurs in
CHF. In the Prospective Randomized Amlodipine Survival
Evaluation (PRAISE) trial [42], the calcium channel blocker
amlodipine was found to reduce IL-6 levels, which has also
been suggested to be important to the beneficial effect of this
agent on mortality in patients with IDCM. However, amlodipine
had no effect on TNF-α levels. Furthermore, we recently
showed that high-dose ACE inhibition with enalapril causes a
marked decrease in IL-6 bioactivity, associated with reduction
in left ventricular septum thickness [43]. Thus, it is possible
that an important ‘antihypertrophic’ mechanism of ACE
inhibitors on the myocardium may be a reduction in IL-6 levels,
possibly combined with impaired IL-6 signal transduction.
Except for a favourable effect on IL-6, all of the other immuno-
logical parameters were markedly elevated in CHF patients
and remained unchanged during treatment with enalapril.
Interestingly, other investigators have reported that ACE
inhibitors may prevent nuclear factor-κB activation and MCP-1
expression, and reduce macrophage infiltration in both experi-
mental and clinical atherosclerosis [44,45]. Additionally, a
combination of ACE inhibitors and angiotensin receptor
antagonists was recently found to reduce cardiac infiltration
of macrophages following acute myocardial infarction in rats
[46]. Whether ACE inhibitors have such effects in CHF
patients must be addressed in future studies.
Several studies have shown that β-adrenergic stimulation may
modulate cytokine production in various lymphocyte subsets
and monocytes [47]. In rats, adrenergic activation has been
found to increase myocardial expression of inflammatory
cytokines (TNF-α and IL-1), which was reduced by β-adrener-
gic blockade (metoprolol) [48]. This may not to be the case in
CHF patients, however. A non-placebo-controlled study in
patients with IDCM [49] reported some suppressive effects
of β-blockers on plasma levels of both inflammatory (TNF-α)
and anti-inflammatory (IL-10) cytokines. However, we have
recently shown [50] that long-term treatment with the β1-
selective blocker metoprolol CR/XL had no significant effect
on cytokine levels, as compared with placebo, in patients with
CHF. It remains to be determined whether more complete
blockade of the β-receptors (i.e. nonselective), or combined
α- and β-blockade with carvedilol alters the cytokine network.
Finally, several studies have suggested that statins may exert
direct cardiovascular effects, such as attenuating inflamma-
tory responses and promoting plaque stability, that are clearly
independent of their cholesterol-lowering effects. Statins
reduce C-reactive protein (CRP) levels and may be effective
in preventing coronary events in patients with relatively low
lipid levels but with elevated CRP [51]. Standard aspirin
treatment also appears to reduce IL-6 and CRP levels in
patients with stable angina [52]. Reduction in cytokine and
CRP levels by statins and aspirin may well explain part of their
therapeutic action. However, their effects in reducing sys-
temic and myocardial inflammation in CHF patients require
further assessment.
The cytokine network as new targets for
therapy in myocardial failure?
Although traditional cardiovascular treatment may have some
immunomodulatory effects, the persistent immune activation
in CHF patients appears generally to be unmodified by these
medications. Several forms of anticytokine and immunomudu-
latory therapy, in addition to conventional cardiovascular
treatment regimens, have recently emerged as possible new
and promising treatment modalities in these patients
(Table 1) [53–61].
Etanercept
Given the central role of TNF-α in the pathogenesis of CHF,
therapeutic modulation targeting this cytokine has received
much attention. Preliminary reports suggest that TNF-α inhibi-
tion with recombinant chimeric soluble TNF receptor type 2
(etanercept) may have beneficial effects on cardiac perfor-
mance in CHF patients [53,54]. However, anticytokine
therapy with soluble TNF receptors may have some limita-
tions. Recent studies in animal models showed that, although
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such therapy decreased plasma cytokine levels, there was no
decrease in IL-6 and MCP-1 levels within the myocardium.
Notably, the Randomized Etanercept North American Strat-
egy to Study Antagonism of Cytokine (RENAISSANCE) and
the Research into Etanercept: Cytokine Antagonism in Ven-
tricular function (RECOVER) outcome studies of etanercept
were recently stopped because of lack of evidence of benefi-
cial effects [62,63]. The studies had randomized over 1500
patients and were due to be completed at the end of 2001,
but interim analysis revealed no likelihood of a difference
between etanercept and placebo developing if the studies
had run to completion.
Pentoxifylline
Pentoxifylline is a xanthine-derived agent that has been shown
to inhibit various inflammatory cytokines such as TNF-α, IL-1β
and interferon-γ. Recently, addition of pentoxifylline to treat-
ment with digoxin, ACE inhibitors and carvedilol in patients
with IDCM was shown to be associated with a significant
improvement in symptoms and LVEF [55,56]. That was in a
single-centre, prospective, double-blind, randomized,
placebo-controlled study. Thirty-nine patients with IDCM and
LVEF below 40% were randomly assigned to pentoxifylline
(400 mg three times daily; n = 20) or placebo (n = 19).
Although the published studies with etanercept and pentoxi-
fylline are small, the improvement in LVEF appears to be
greater with pentoxifylline. Furthermore, other advantages of
pentoxifylline over etanercept are its easier form of adminis-
tration, lower cost and that it might inhibit the production of
TNF-α rather than neutralize its effects. Although large-scale
trials are needed to evaluate the safety of pentoxifylline in
patients with CHF, this drug has been used in patients with
peripheral vascular disease for more than 25 years with a very
low incidence of side effects.
Intravenous immunoglobulin
Therapy with IVIG has been evaluated in a wide range of
immune-mediated disorders, such as Kawasaki syndrome,
dermatomyositis and multiple sclerosis [64,65]. Beneficial
effects of IVIG have also been suggested in acute and peri-
partum cardiomyopathy [66,67].
Recently, we demonstrated that IVIG significantly improves
LVEF by 5% in CHF patients, independent of the aetiology of
heart failure [58]. That was a double-blind, placebo-controlled
study, with 40 CHF patients (both ischaemic and IDCM with
LVEF below40%). IVIG also improved some haemodynamic
variables (pulmonary capillary wedge pressure) and exercise
capacity. IVIG, but not placebo, was accompanied by a marked
but gradual decline in plasma levels of amino-terminal pro-atrial
natriuretic peptide. In contrast, a recent study conducted by
McNamara et al. [68] found no significant impact of IVIG, as
compared with placebo, on recent-onset IDCM. Although this
may be due to the marked improvement in the study group as a
whole (with or without IVIG), it is noteworthy that the dosage
schedule differs between the ‘IDCM’ and the ‘CHF’ study.
Although both studies described above gave induction
therapy, maintenance therapy (monthly infusions for a total of
5 months) was only given in the ‘CHF’ study [58]. Notably, in
the ‘CHF’ study there was as a gradual decline in amino-ter-
minal pro-atrial natriuretic peptide throughout, which became
pronounced at the end of study. Moreover, a recent follow-up
study (Gullestad L, Aukrust P, unpublished data) showed that
most of the CHF patients in the IVIG group had a decrease in
LVEF 1 year after termination of the study. Those data
suggest that maintenance therapy is needed for an extended
period of time, as in other chronic inflammatory disorders.
Several modes of action may be of importance for the clinical
effects of IVIG in inflammatory disorders, such as neutraliza-
tion of microbial antigens, Fc-receptor blockade and impair-
ment of apoptosis [64,69]. In our opinion, however, particular
attention should be drawn toward the effect of IVIG on the
cytokine network. In the IVIG study the improvement in LVEF
was associated with a marked rise in the anti-inflammatory
mediators IL-10, IL-1 receptor antagonist and soluble TNF
receptor, which was accompanied by a slight decrease in
TNF-α and IL-1β [58]. This suggests an anti-inflammatory net
effect with potential beneficial results on the myocardium.
Taken together with the imbalance between pro- and anti-
inflammatory cytokines in CHF patients [11], upregulation or
administration of anti-inflammatory cytokines such as IL-10
might be a useful strategy for intervention in CHF patients.
Interestingly, administration of IL-10 has recently been shown
to have therapeutic effects on murine viral myocarditis [59].
Finally, we also reported that IVIG therapy, but not placebo,
may downregulate chemokines and their receptors on periph-
eral blood mononuclear cells in CHF patients, possibly con-
tributing to the beneficial effect of IVIG in CHF [61].
Accordingly, direct blockade of the chemokine network may
represent another interesting approach for future intervention
in CHF patients.
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Table 1
Immunomodulation in heart failure: potential treatment
modalities
Agent References
Soluble tumour necrosis factor receptors (etanercept) [53,54]
Pentoxifylline [55,56]
Thalidomide [57]
Intravenous immunoglobulin [58]
Interleukin-10 [59]
Interleukin-1 receptor antagonist [60]
Chemokine modulators [61]
Recently, the technique of immunoadsorption has been used
in several studies to treat patients with IDCM [70].
Immunoadsorption has been found to improve functional
capacity, and left ventricular structure and function in IDCM
patients [70]. The mechanisms that underlie these effects
may involve removal of circulating antibodies to β1-adreno-
receptors, reduction in oxidative stress and mitigation of
myocardial inflammation [70–72]. IVIG replacement therapy
is often given to these patients and, as discussed above, may
per se lead to improvement in clinical status in patients with
IDCM [58,70].
Conclusion
Although not necessarily the ‘drugs of choice’, recent studies
of various anticytokine (etanercept) and immunomodulating
agents (IVIG and pentoxifylline) in CHF patients clearly
suggest a potential for such therapies in these patients, in
addition to ‘optimal’ cardiovascular treatment regimens.
However, the results in these small studies will have to be
confirmed in larger, placebo-controlled mortality studies.
Several studies have focused on the possible pathogenic role
of TNF-α, and targeted therapy against this molecule is
ongoing. In order to develop more specific immunomodulat-
ing agents in the immunopathogenesis of CHF, further
research will need to identify precisely the important players.
Regardless of these shortcomings, we believe that cytokines
might lead to quite new treatment modalities in CHF, result-
ing in reduced morbidity and mortality in such patients.
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